Q1 EPS Estimate for Theravance Biopharma Lowered by Analyst
Theravance Biopharma, Inc. (NASDAQ:TBPH – Free Report) – Equities researchers at Zacks Research cut their Q1 2025 earnings estimates for Theravance Biopharma in a research note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.43) per share for the quarter, down from their […]
Theravance Biopharma, Inc. (NASDAQ:TBPH – Free Report) – Equities researchers at Zacks Research cut their Q1 2025 earnings estimates for Theravance Biopharma in a research note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.43) per share for the quarter, down from their […]
